ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 154,100 shares, a decrease of 25.2% from the October 15th total of 206,100 shares. Based on an average daily trading volume, of 83,200 shares, the short-interest ratio is presently 1.9 days.

ProPhase Labs Price Performance

NASDAQ PRPH remained flat at $0.75 on Friday. 132,407 shares of the company’s stock traded hands, compared to its average volume of 249,771. ProPhase Labs has a 12 month low of $0.66 and a 12 month high of $7.48. The firm has a fifty day simple moving average of $2.16 and a 200-day simple moving average of $3.24. The firm has a market cap of $17.90 million, a P/E ratio of -0.60 and a beta of -0.10. The company has a current ratio of 1.47, a quick ratio of 1.44 and a debt-to-equity ratio of 0.48.

ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.25). ProPhase Labs had a negative return on equity of 62.92% and a negative net margin of 217.64%. The firm had revenue of $2.47 million for the quarter. As a group, equities research analysts predict that ProPhase Labs will post -1.23 EPS for the current fiscal year.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently made changes to their positions in PRPH. Geode Capital Management LLC increased its stake in ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares during the last quarter. HighTower Advisors LLC grew its position in shares of ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after buying an additional 27,673 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in ProPhase Labs by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock worth $4,003,000 after acquiring an additional 9,416 shares in the last quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.